Moderna and BioNTech plummet more than 15% following news of Merck’s COVID-19 antiviral pill
The antiviral drug could put a dent into the uptake of COVID-19 vaccines, as countries still struggle to reach herd immunity due to vaccine hesitancy.
Cynata seals partnership for US stem cell therapy push
Biotechnology company Cynata Therapeutics has sealed a partnership agreement with Fujifilm as it moves towards a commercial manufacturing deal for its proprietary Cymerus stem cell therapy products…
Pfizer / BioNTech Submit Initial Covid-19 Vaccine Data For People Aged 5-11 To FDA, But Not Yet Researching EUA
Submissions to the European Medicines Agency and other regulatory authorities are also planned, they said. This is the first data submission to the FDA for a Covid-19 vaccine for young children. The Pfizer / BioNTech vaccine is approved for people 16 years of age and older and has an EUA for people 12 to […]
Defra “unlocks power” of gene editing
Defra takes first step towards allowing gene-editing techniques in UK crop farming, provoking alarm from Soil Association
Pfizer and BioNTech Submit Initial Data to U.S. FDA From Pivotal Trial of COVID-19 Vaccine in Children 5 to
NEW YORK and MAINZ, Germany–(BUSINESS WIRE)–Sep 28, 2021–
Acrigen Biosciences Raises Seed Financing to Advance Precision Gene Editing Technology and Therapeutic Pipeline
Press release content from Business Wire. The AP news staff was not involved in its creation.
Moderna CEO says enough COVID vaccine will be available to return to normal ‘in a year’
He said he assumed that things can return to normal ‘in a year.”
Jeff Bezos invests in anti-ageing biotech startup to reprogram human cells: Report
Research-based company Altos Labs, founded in the first half of 2021, has claimed to have Jeff Bezos on board as one of their investors.
BIORCHESTRA appoints pharma veteran and Moderna and Akcea (Ionis) CMO “Dr. Louis St. L. O’Dea” as CMO of BIORCHESTRA
Press release content from PR Newswire. The AP news staff was not involved in its creation.
Biogen loses $7 billion in value on slow Alzheimer’s drug rollout
Only about 50 sites have been infusing the medication since June, well below company’s prior target of 900 centers, according to RBC analyst Brian Abrahams.